特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
925256

乳がんリキッドバイオプシー市場 - 成長、傾向、予測

Breast Cancer Liquid Biopsy Market - Growth, Trends, and Forecast (2020 - 2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 120 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
乳がんリキッドバイオプシー市場 - 成長、傾向、予測
出版日: 2020年02月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 120 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の乳がんリキッドバイオプシー市場は、2020年から2025年にかけて18.9%超のCAGRで拡大すると予測されています。乳がんの有病率の上昇と、より低侵襲な治療法に対する需要の増加が市場を牽引しています。

当レポートでは、乳がんリキッドバイオプシーの世界市場を調査し、市場の概要、タイプ、地域別の市場動向、市場規模の推移と予測、市場促進・阻害要因ならびに市場機会の分析、競合情勢、主要企業のプロファイルなど包括的な情報を提供しています 。

目次

第1章 イントロダクション

  • 調査の前提条件
  • 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場のダイナミクス

  • 市場概要
  • 市場概要
  • 成長要因
  • 抑制要因
  • ファイブフォース分析
    • 新規参入の脅威
    • 消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内での競争

第5章 市場セグメンテーション

  • 循環バイオマーカー別
    • 循環腫瘍細胞(CTC)
    • 循環無細胞DNA(cfDNA)
    • 細胞外小胞
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • QIAGEN
    • F. Hoffmann-La Roche Ltd
    • Bio-Rad Laboratories Inc
    • Janssen Diagnostics
    • Biocept Inc
    • Guardant Health, Inc
    • Myriad Genetics
    • Adaptive Biotechnologies
    • Epic Sciences
    • Illumina, Inc

第7章 市場機会および将来動向

目次
Product Code: 67698

The Breast Cancer Liquid Biopsy Market is expected to register a CAGR of 18.9% during the forecast period. Breast cancer liquid biopsy is the method of detecting or investigating tumor cells in the blood sample obtained from the target cancerous site. For the detection of breast cancer, traditional methods like tissue biopsies are not comprehensive enough to predict or capture the entire genomics landscape of breast tumors. However, the presence of liquid biopsy as an alternative method allows for many clinical applications, including screening, detection of mutations, therapy selection, disease prognosis and drug response and resistance in patients who are unable to undergo an invasive tumor biopsy. According to World Health Organization (WHO), breast cancer is the most frequent type of cancer among women globally, approximately 2.1 million women suffer from breast cancer every year, and it leads to highest number of cancer-related deaths among women. In the year 2018, it was estimated that approximately 627,000 women died from breast cancer that is nearly 15% of all cancer deaths among women globally. Rising prevalence of breast cancer and increasing demand for better minimally invasive therapies are the key driving factors in breast cancer liquid biopsy market.

Key Market Trends

Circulating Cell-free DNA (cfDNA) Segment is Expected to Hold a Major Market Share in the Breast Cancer Liquid Biopsy Market

  • Circulating cell-free DNA (cfDNA) refers to extracellular degraded DNA fragments present in blood and other body fluids that may be derived from both normal and diseased cells. The concentration, genetic and epigenetic alternations in the circulating cell-free DNA may suggest pathological conditions of the body such as autoimmune diseases, stress, inflammation, and malignancies.
  • According to the World Health Organization (WHO), in the year 2018, it was estimated that approximately 627,000 women died from breast cancer that is nearly 15% of all cancer deaths among women globally.
  • Circulating cell-free DNA segment holds a significant market share in the breast cancer liquid biopsy market and is anticipated to show a similar trend over the forecast period due to its occurrence in blood and other body fluids of cancer patients.
  • Rising incidence of breast cancer cases and growing demand for non-invasive treatment are the key driving factors in the circulating cell-free DNA (cfDNA) segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global breast cancer liquid biopsy market due to the rising incidence of breast cancer cases and growing demand for non-invasive treatment in this region. According to the National Breast Cancer Foundation, in the year 2019, 62% of breast cancer cases were diagnosed at a localized stage. Female breast cancer represents approximately 15.2% of all new cancer cases in the United States. Furthermore, the high adoption rates of advanced diagnostic technologies such as PCR and NGS among healthcare professionals and presence of well-established healthcare infrastructure is fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Breast Cancer Liquid Biopsy Market is highly fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are QIAGEN, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Janssen Diagnostics, Biocept Inc, Guardant Health, Inc, Myriad Genetics, Adaptive Biotechnologies, Epic Sciences and Illumina, Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Breast Cancer
    • 4.2.2 Increasing Demand for Better Minimally Invasive Therapies
    • 4.2.3 Technological Advancements in the Early Stage Detection of Breast Cancer
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Issues
    • 4.3.2 Poor Reimbursement Policies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Circulating Biomarkers
    • 5.1.1 Circulating Tumor Cells (CTCs)
    • 5.1.2 Circulating cell-free DNA (cfDNA)
    • 5.1.3 Extracellular Vesicles
    • 5.1.4 Other Circulating Biomarkers
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 QIAGEN
    • 6.1.2 F. Hoffmann-La Roche Ltd
    • 6.1.3 Bio-Rad Laboratories Inc
    • 6.1.4 Janssen Diagnostics
    • 6.1.5 Biocept Inc
    • 6.1.6 Guardant Health, Inc
    • 6.1.7 Myriad Genetics
    • 6.1.8 Adaptive Biotechnologies
    • 6.1.9 Epic Sciences
    • 6.1.10 Illumina, Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.